Bremelanotide acetate is under clinical development by Cosette Pharmaceuticals and currently in Phase II for Obesity.

Data showed a 90.6% rate of correct consumer self-selection among those who used the Web App Technology with the DFL vs 57.3% among those that used the DFL alone.

Palatin Technologies has dosed the first subjects in a Phase II clinical trial evaluating the co-administration of bremelanotide with tirzepatide to treat obesity. Bremelanotide is a melanocortin ...

Credit: SofikoS/Shutterstock. Palatin Technologies has dosed the first subjects in a Phase II clinical trial evaluating the co-administration of bremelanotide with tirzepatide to treat obesity.

Patients will undergo multiple assessments of safety and efficacy to help profile the effectiveness of bremelanotide in treating general obesity as a stand-alone treatment or in conjunction with ...